Date: 2018-09-25
Type of information: Nomination
Compound: member of the board of directors
Company: KSQ Therapeutics (USA - MA)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On September 25, 2018, KSQ Therapeutics announced the appointment of Richard A. Moscicki to the company’s board of directors. Dr. Moscicki brings more than 25 years of leadership experience in translational medicine, clinical development, regulatory affairs and medical affairs in the pharmaceutical industry. He is currently the Executive Vice President for Science and Regulatory Advocacy and the Chief Medical Officer at Pharmaceutical Research and Manufacturers of America (PhRMA). From 2013 to 2017, prior to joining PhRMA, he served as the Deputy Center Director for Science Operations for the FDA’s Center for Drug Evaluation and Research (CDER). Dr. Moscicki was senior vice president and head of Clinical Development at Sanofi-Genzyme from 2011-2013. He was Chief Medical Officer at Genzyme Corporation from 1992 to 2011, where he was responsible for worldwide global regulatory and pharmacovigilance, as well as all aspects of clinical research and medical affairs. Dr. Moscicki is board certified in internal medicine, diagnostic and laboratory immunology, and allergy and immunology. He completed his residency in internal medicine, followed by a fellowship at Massachusetts General Hospital in clinical immunology and immunopathology. He remained on staff at MGH and on the faculty of Harvard Medical School from 1979 until 2013. Dr. Moscicki received his medical degree from Northwestern University Medical School.
Financial terms:
Latest news:
Is general: Yes
